We have a rich pipeline of drug development and biomarker programs that we are now rapidly moving forward.

With one drug having just completed a Phase I clinical trial and two other programs in pre-clinical work being prepared for clinical development in 2010 and 2011, AnaMar's current top priority is to generate quality clinical data that will position each of these programs for strategic partnerships with one or several pharmaceutical/biotech companies.

Recognizing the need to position each of our drug programs for suitable strategic alliances as described above, AnaMar is prepared to take these programs to proof of concept on its own, including initial Phase II clinical trials.

Other priorities include continued work on development of the biomarker pipeline and to continue building our pipeline with novel product ideas from a variety of sources, ranging from our proprietary in-house discovery to research agreements.